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Abstract
Objective. Inflammatory arthritis in childhood is variable in terms of both presentation and outcome. This
analysis describes disease activity in children with juvenile idiopathic arthritis (JIA) during the first year
following presentation to a paediatric rheumatologist and identifies predictors of moderate to severe
disability [defined using a Childhood HAQ (CHAQ) score 50.75] at 1 year.
Methods. The Childhood Arthritis Prospective Study recruits children <16 years with new inflammatory
arthritis persisting for 52 weeks from five UK tertiary referral centres. Demographics, disease features,
joint count, CHAQ, physician’s global assessment, parent’s general evaluation of well-being (PGE), ESR
and treatment, are collected at first presentation, 6 months and then yearly. Independent predictors
of CHAQ 50.75 at 1 year in children diagnosed with JIA were identified using multivariable logistic
regression models.
Results. Seven hundred and forty children with JIA were included; median age at presentation 7.6 years,
64% girls. During the first year, 85% received NSAIDs, 70% IA corticosteroids, 47% MTX and 27%
systemic steroids (oral or i.v.). Median presenting CHAQ score was 0.63 and decreased to 0.25 at 1
year; 32% had CHAQ 50.75 at 1 year. The strongest predictor of CHAQ 50.75 at 1 year was CHAQ
50.75 at presentation (odds ratio 3.92; 95% CI 2.17, 7.09). Additional predictors included female gender
and higher PGE
Conclusion. Although CHAQ score improved in most children, the strongest predictor of persistent
disability at 1 year was moderate to severe disability at first presentation. Follow-up beyond 1 year will
assess whether CHAQ at presentation will continue to be a predictor of future poor outcome.
Key words: Juvenile idiopathic arthritis, Disability, Outcomes, Disease activity.
Introduction
Inflammatory arthritis is a chronic debilitating disease
of childhood. It has been estimated that each year,
 10/100000 children will develop an inflammatory
arthritis [1], with many subsequently being diagnosed
with juvenile idiopathic arthritis (JIA). Although the disease
course can be variable, with periods of activity followed by
remission, previous studies have shown that up to 70% of
children continue to report disability and limitation of their
activities into adulthood [2–7]. However, comparison
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including variability in the classification of childhood arthri-
tis [8–12], differences in study design and changes in
treatments over time. In addition, most of these previous
studies have based estimates of the chronicity and
severity of this disease on retrospective medical record
reviews, which may bias towards a more severe group
of patients. As a result, many studies lack specific
measures of disease activity at first presentation, making
it difficult to predict later outcomes based on early
presentation.
Finally, the change in the treatment of JIA towards
earlier aggressive therapy is likely to have changed out-
comes for many groups of patients, thus making previous
estimates of outcomes less applicable to children today.
Therefore, data concerning the early disease course in
children presenting with inflammatory arthritis in this
modern treatment era remains limited and there is a
need to study prospective inception cohorts of children
with inflammatory arthritis such that all aspects of the
disease course can be captured, from the very mild to
the most severe. Identifying early those children who are
most likely to have a severe disease course may help to
target therapies to those most likely to have poor
outcomes and avoid over-treatment in those most likely
to experience spontaneous remission.
The Childhood Arthritis Prospective Study (CAPS) is an
ongoing prospective longitudinal inception cohort study,
which aims to provide information on the long-term
outcome of children with inflammatory arthritis following
routine care in the UK. The aim of the current analysis was
to describe the outcomes of children with JIA 1 year
following first presentation to paediatric rheumatology
and to identify factors that predicted moderate to severe
disability at 1 year.
Methods
Studypopulation
The CAPS study began recruitment in 2001. Details of
this study have been described elsewhere [13]. In brief,
children aged <16 years presenting to one of five paedia-
tric rheumatology referral centres (Liverpool, Manchester,
Glasgow, Newcastle-upon-Tyne and London) with a new
diagnosis of inflammatory arthritis (in at least one joint)
present for at least 2 weeks are approached to partici-
pate. Exclusion criteria are septic arthritis, haemarthrosis,
arthritis caused by malignancy or trauma, connective
tissue disorders such as SLE, MCTD or DM. Currently,
the study continues to recruit new children. The study
was approved by the UK Northwest Multicentre
Research Ethics Committee. Written informed consent
was obtained from the parent(s)/guardian for all partici-
pant children and children, if considered able, provided
assent.
Baseline data collection
At the first visit, the rheumatologist performs a rheumato-
logical exam and completes a 100-mm physician’s global
assessment (PGA). They are asked to assign an
International League Against Rheumatism (ILAR) subtype
if the suspected diagnosis is JIA. The parent(s) and child
are interviewed by a rheumatology research nurse and the
medical records are reviewed to extract information on
demographics, diagnosis, disease characteristics includ-
ing disease duration at first presentation, past medical
history, medications and relevant blood tests. Blood
tests are only done as part of routine care and results
are recorded when performed. The parent (or where
appropriate the child) completes a Childhood HAQ
(CHAQ) validated for use in the UK population [14], a
100-mm pain visual analogue scale (VAS) and a 100-mm
parent general evaluation (PGE).
Follow-up data
Follow-up study visits are arranged at 6 months following
first presentation and then yearly for a minimum of
5 years. At each follow-up, the child again undergoes
a rheumatological examination, and the PGA, PGE,
CHAQ and a pain VAS are completed. Again, details of
medications taken since last follow-up are extracted from
the medical record, as are results of any relevant blood
tests. Children who are discharged from rheumatology
care continue to be followed by the rheumatology
research nurse for at least two additional years.
Analysis
This analysis was limited to children with a diagnosis of
JIA (that is, arthritis persisting for 56 weeks in one
or more joint, of no other attributable cause) who had
completed at least 1 year of follow-up. Demographic
and disease characteristics including the JIA core out-
come variables (active and limited joint count, PGA,
PGE, CHAQ score and ESR) and pain measured at first
presentation and at 1 year are presented for the entire
cohort and by ILAR subtype. A joint was considered
active if there was swelling due to active synovitis or in
the absence of swelling, limited motion accompanied by
heat, pain or tenderness [15]. A limited joint was a joint
limited in motion. The ILAR subtype for this analysis
was assigned at 6 months of symptom duration.
If children had been symptomatic for >6 months at first
paediatric rheumatology visit, the ILAR subtype was
assigned at the first presentation. If the child had been
symptomatic for <6 months, the subtype was assigned
at the 6-month follow-up visit. The values of each disease
characteristic at baseline and at 1 year were compared
within the whole cohort and within each individual subtype
using Wilcoxon matched-pairs test.
A CHAQ score 50.75 was selected to indicate moder-
ate to severe levels of disability. Previous studies which
have attempted to correlate CHAQ scores with parent or
child reports of the level of disability have found a value of
0.75 to be a good discriminant between none to mild and
moderate to severe disability [16, 17]. Multivariable
logistic regression models were developed to identify (i)
factors associated with this high CHAQ at baseline and
(ii) predictors (measured at first presentation) of a high
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Disease activity in children with JIACHAQ at 1 year. Co-variates in the models included age at
first presentation, gender, study site, symptom duration at
first presentation (defined using month of first reported
symptom onset), active and limited joint count, ESR
(per 10mm/h increments), PGA (per 10mm increments),
PGE (per 10mm increments) and pain score (per 10mm
increments). Missing data were imputed using multiple
imputation (number of repeated imputations¼35)
[18, 19]. The following variables were included in the
imputation: age, gender, symptom duration, active joint
count, ESR, PGA, PGE, CHAQ and pain scores.
Regression models were run with both unimputed and
imputed data and the results of both are presented. The
results are presented as odds ratios (ORs) with 95% CIs.
All analyses were performed in Stata version 9.2
(Statacorp 2003, College Station, TX, USA).
Results
Up to March 2009, CAPS had registered 917 cases with
JIA. Of these, 740 had reached 1 year of follow-up. The
study participants were primarily Caucasian (93%) with a
median age at first presentation of 7.6 years [interquartile
range (IQR) 3.6–11.5]; 64% were females (Table 1). The
median symptom duration at first presentation was
5.2 months (IQR 2.5–10.4). The most common ILAR
subtype was oligoarthritis (48%). At first presentation,
the median active joint count was 2 (IQR 1–5). The
median ESR was 20mm/h (IQR 6–46), median pain
score was 32 (IQR 9–57) and the median CHAQ was
0.63 (IQR 0.13–1.38) (Tables 2 and 3). For 91 children
(19%), the presenting CHAQ score was 0.
After 1 year of follow-up, all subtypes of JIA had
experienced improvements in scores (Tables 2 and 3).
The median active and limited joint count at 1 year was
0 (IQR 0–1). The median ESR had fallen to 9 (IQR 4–20)
and the median pain score had decreased to 9 (IQR 1–32).
CHAQ scores had also improved with a median CHAQ
score of 0.25 (IQR 0.00–1.00) at 1 year. Twenty-six per
cent had a CHAQ score of 0 at 1 year. The one exception
was a deterioration in the PGE in children with RF(þ)
polyarthritis, although this did not reach statistical signifi-
cance. Of those presenting with oligoarthritis in the first
6 months (n¼353), 16 (5%) children had evolved to the
extended subtype at 1 year. Although small numbers
prevent robust estimates, there were no significant differ-
ences in age, gender, active or limited joint counts or ESR
at first presentation between those children with
persistent oligoarthritis and those who extended.
Over the course of the first year following presentation,
85% of children received treatment with NSAIDs (Table 4),
70% of children had received an IA steroid injection, with
a median of one injected joints/child (range 1–35) and
47% had started on MTX. Approximately half of the
children had received their first dose of MTX within 6
months of disease onset [n¼169 (48%)]. Eighty-seven
per cent of children had received their first dose of MTX
within 6 months of first presentation to a paediatric
rheumatologist and 57% within the first month following
presentation. Seven per cent of children had already
received biologic therapy before the end of the first year.
CHAQ score 50.75 at first presentation was signifi-
cantly associated with active joint count, ESR, PGE and
pain scores (Table 5). At 1 year, the proportion of children
with a CHAQ score 50.75 had fallen from 50 to 32%. The
highest scores were again seen in children with systemic
arthritis, polyarthritis [RF(þ) and RF( )] and extended
oligoarthritis. The majority of children with a CHAQ
score <0.75 at first presentation continued to have a
CHAQ <0.75 at 1 year although 14% of children with an
initial low CHAQ had a 1 year CHAQ 50.75. The strongest
predictor of a CHAQ score 50.75 at 1 year was a CHAQ
score 50.75 at first presentation (OR 3.92; 95% CI 2.17,
7.09). In addition, higher CHAQ scores at 1 year were less
common in boys (OR 0.62; 95% CI 0.37, 1.03) and more
common in those with higher PGE at baseline (OR 1.16
per 10-mm VAS; 95% CI 1.01, 1.32). Other factors, includ-
ing symptom duration at first presentation, ESR, pain
scores and PGA were not independently associated
with CHAQ 50.75 at 1 year.
Discussion
This study represents the largest prospective report of
early outcomes in a modern inception cohort of children
presenting to paediatric rheumatology with inflammatory
TABLE 1 Demographic characteristics at first presentation to a paediatric rheumatologist
ILAR
n
(% of total)
Age at symptom
onset, median (IQR), years
Age at first presentation,
median (IQR), years
Female, n (% within
each subtype)
Whole cohort 740 (100) 6.6 (2.8, 10.7) 7.6 (3.6, 11.5) 476 (64)
Systemic arthritis 42 (6) 6.4 (3.4, 10) 6.7 (3.6, 10.1) 32 (76)
Persistent oligoarthritis 353 (48) 5.5 (2.4, 9.8) 6.5 (3.1, 10.8) 225 (64)
Extended oligoarthritis 32 (4) 4.3 (1.9, 8.4) 5.3 (2.7, 9.4) 23 (72)
RF( ) polyarthritis 148 (20) 5.8 (2.2, 9.4) 7.5 (3.3, 10.6) 110 (74)
RF(þ) polyarthritis 23 (3) 11.4 (9.1, 13.4) 12.2 (9.9, 14.8) 21 (91)
ERA 51 (7) 11.8 (10.1, 13.1) 13 (11.3, 13.9) 6 (12)
PSA 61 (8) 9.8 (4.3, 11.6) 11 (5.7, 13) 40 (66)
Undifferentiated 30 (4) 7.1 (2.7, 9.8) 8.9 (5.8, 10.9) 19 (63)
ERA: enthesitis related arthritis.
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Kimme L. Hyrich et al.arthritis. In addition, the results are not limited to a single
centre or rheumatologist, but represent the current
outcomes at five of the largest paediatric rheumatology
centres in the UK, which practise within the guidelines
as set out by the British Society for Paediatric and
Adolescent Rheumatology (BSPAR) consensus document
on the standards of care for children and young people
with JIA (http://www.bspar.org.uk/downloads/clinical_
guidelines/Standards_of_Care.pdf).
Over 50% of children presented with oligoarthritis and a
significant proportion of children were found to have no
active or limited joints at the 1 year assessment. However,
even in this era of modern therapies, there still remained a
subgroup of children with persistently active disease. Not
surprisingly, the strongest predictor of disability at 1 year
was the level of disability at the first presentation, which
likely encompasses many other features of the disease,
including active joint counts and pain. High levels of
TABLE 2 Disease activity at baseline and 1 year
Active joint count Limited joint count ESR (mm/h)
ILAR Baseline 1 year Baseline 1 year Baseline 1 year
Whole cohort 2 (1–5) 0 (0–1)* 1 (1–3) 0 (0–1)* 20 (6–45) 9 (4–20)*
Systemic arthritis 3 (1–6) 0 (0–1)* 0 (0–4) 0 (0–0)* 85 (55–102) 25 (5–43)*
Persistent oligoarthritis 1 (1–2) 0 (0–1)* 1 (1–2) 0 (0–1)* 13 (5–30) 8 (5–16)*
Extended oligoarthritis 3 (1–6) 0 (0–1)* 2 (1–4) 1 (0–1)* 34 (13–53) 15 (9–32)
RF( ) polyarthritis 8 (4–14) 0 (0–2)* 5 (2–11) 1 (0–3)* 28 (8–56) 8 (4–21)*
RF(þ) polyarthritis 7 (5–22) 1 (0–5)* 2 (1–16) 1 (0–2) 18 (10–46) 12 (6–16)*
ERA 2 (1–5) 0 (0–1)* 2 (1–4) 0 (0–2)* 16 (7–32) 8 (3–14)*
PSA 3 (2–5) 0 (0–2)* 2 (1–3) 1 (0–2)* 26 (8–43) 8 (3–17)*
Undifferentiated 1 (1–6) 0 (0–1)* 1 (1–5) 0 (0–2)* 14 (6–35) 10 (5–48)
Physician global score PGE Pain score
Baseline 1 year Baseline 1 year Baseline 1 year
Whole cohort 31 (18–56) 6 (1–18)* 20 (5–46) 6 (1–27)* 32 (9–57) 9 (1–32)*
Systemic arthritis 57 (35–72) 14 (3–31)* 33 (7–53) 9 (3–36)* 42 (10–50) 19 (7–50)
Persistent oligoarthritis 24 (15–43) 2 (0–17)* 15 (3–39) 4 (0–21)* 24 (7–50) 6 (0–30)*
Extended oligoarthritis 36 (20–61) 8 (4–21)* 27 (7–48) 9 (2–36) 36 (7–50) 14 (1–30)
RF( ) polyarthritis 47 (30–67) 9 (2–18)* 32 (8–53) 7 (2–26)* 39 (12–70) 8 (2–25)*
RF(þ) polyarthritis 39 (22–67) 9 (4–27)* 19 (15–32) 42 (36–70) 61 (21–65) 41 (20–59)*
ERA 31 (21–55) 8 (0–15)* 22 (12–50) 5 (0–35)* 49 (21–64) 8 (0–51)
PSA 30 (17–45) 6 (1–18)* 18 (3–33) 8 (3–24) 26 (9–55) 9 (2–32)*
Undifferentiated 22 (11–43) 8 (1–24)* 16 (2–28) 8 (1–34) 21 (1–66) 10 (1–26)*
Values are given as median (IQR). *Improvement at 1 year statistically significant at P<0.05. ERA: enthesitis related arthritis.
TABLE 3 Disability (measured using CHAQ score) at first presentation and at 1 year in children with JIA
CHAQ at first presentation CHAQ at 1 year
JIA ILAR subtype Median (IQR)
Percentage
with CHAQ
50.75 Median (IQR)
Percentage
with CHAQ
50.75
Whole cohort 0.63 (0.13–1.38) 50 0.25 (0–1.0)* 32
Systemic arthritis 0.94 (0.25–2.0) 54 0.5 (0.06–1.5) 47
Persistent oligoarthritis 0.63 (0.13–1.13) 46 0.13 (0–0.75)* 27
Extended oligoarthritis 0.56 (0.38–1.5) 45 0.56 (0.06–1.19) 42
RF( ) polyarthritis 1.25 (0.38–1.88) 65 0.38 (0.13–1.5)* 40
RF(þ) polyarthritis 1.13 (0.5–1.5) 64 0.56 (0.13–1.13)* 40
ERA 0.5 (0.06–1.19) 44 0.13 (0–0.5)* 24
PSA 0.38 (0.13–1.0) 40 0.13 (0–1.0) 30
Undifferentiated 0.38 (0–1.13) 36 0.19 (0–1.19) 35
*Improvement at 1 year statistically significant at P<0.05. ERA: enthesitis related arthritis.
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Disease activity in children with JIAdisability at first presentation have also been shown to be
a strong predictor of future disability in studies of adults
with RA [20].
In our study, we found an association between higher
levels of disability among girls at 1 year, which is consis-
tent with earlier reports [21, 22]. Oen et al. [23] specifically
looked at predictors of CHAQ score 50.75 after a mean
of 12 years of disease in her retrospective cohort of
children with JRA. Although specific details of disease
activity at disease presentation were not available, there
was also a trend towards less disability, albeit at a much
later time point in disease, in males. The reasons why
females should do worse than males is not clear.
However, an over-representation of females in certain
subgroups, particularly RF(þ) polyarthritis, which often
has a more severe course, may explain part of the
association.
Few previous studies have specifically looked at the
early course of the disease in children with inflammatory
arthritis and fewer still have specifically classified children
according to the ILAR JIA subtypes, making direct
comparisons of our results difficult. A retrospective
study by Bowyer et al. [24] described outcomes at 1
and 5 years in children with JRA presenting between
1992 and 1997 and found that the vast majority had
milder levels of disability at the end of the first year
(defined as Steinbrocker Class I or II). However, children
with SpAs and/or psoriasis were specifically excluded.
In our study, 24% of the children with enthesitis related
arthritis (ERA) and 30% of the children with PSA had
significant disability (CHAQ 50.75) at 1 year.
The results of our study are similar to those found in
a single-centre inception cohort of 197 children with
JRA or juvenile SpA in Norway [25], which also found
that CHAQ score in the first 6 months of the disease
was the strongest predictor of disability, measured using
CHAQ, at 3 years. Similarly, they also found that the
parent’s global assessment of the child’s well-being was
a predictor of CHAQ at 3 years, suggesting there are other
important aspects of the child’s arthritis observed by
the parent but independent of the physician, which are
important in determining functional outcome.
It is difficult to know at this time point specifically what
role the DMARDs and other anti-rheumatic therapies
played in the improvement of CHAQ scores in these
children and how much was the natural variability within
the disease. An Italian study of 227 children with JIA found
that patterns of disability fluctuated between states of
mild, moderate and severe disability in 40% of the
children measured over a median of 3 years [26]. One-
quarter of the children demonstrated a continuous
improvement in disability over this same period and a
further one-quarter demonstrated persistently stable low
disability levels. Further analyses of the CAPS cohort will
also confirm whether or not early treatment with DMARDs
significantly improves longer term outcome. In this study,
the biggest determinant in how long after the disease
onset MTX was started was the time taken to first paedia-
tric rheumatology assessment, as the majority of children
who did start MTX did so soon after this first appointment.
However, at this stage, delay to first presentation was not
found to be a predictor of high CHAQ at 1 year. Continued
follow-up will determine whether delay to presentation
influences longer term outcomes.
A possible limitation to our study may have been the
impact of missing data. In our study, the two variables
with the most missing data at baseline included the ESR
(23% missing) and the CHAQ score (30% missing). As per
ethical approval, blood tests could only be taken as part of
routine clinical practice and therefore, if an ESR had not
been performed, this value would not be available.
Although most centres now collect CHAQ as part of
routine clinical care, this was not always the case over
the study period. In addition, for some families, due to
circumstances at the time of first presentation, parents
may have been unable to complete these forms at the
first visit. However, despite this missing data, all children
had available information for multiple imputations. To
confirm the validity of our multiple imputations, we also
ran regression models in those with complete data only.
This analysis also confirmed the significant association
with CHAQ 50.75 at baseline and calculated similar
point estimates for PGE and gender, albeit with wider
CIs, likely due to the smaller sample size.
TABLE 4 Details of anti-rheumatic therapies received in first year following presentation
ILAR NSAID Systemic steroids
a IA steroids MTX Biologics
Whole cohort 632 (85) 197 (27) 515 (70) 350 (47) 55 (7)
Systemic arthritis 35 (83) 37 (88) 11 (26) 33 (79) 7 (17)
Persistent oligoarthritis 300 (85) 41 (12) 261 (74) 65 (18) 3 (1)
Extended oligoarthritis 29 (91) 8 (25) 28 (88) 24 (75) 3 (9)
RF( ) polyarthritis 128 (86) 73 (49) 107 (72) 135 (91) 23 (16)
RF(þ) polyarthritis 20 (87) 12 (52) 10 (43) 21 (91) 5 (22)
ERA 45 (88) 13 (25) 32 (63) 22 (43) 7 (14)
PSA 50 (82) 8 (13) 44 (72) 38 (62) 5 (8)
Undifferentiated 25 (83) 5 (17) 22 (73) 12 (40) 2 (7)
Values are given as n (%).
aIncluded either oral or systemic steroids. ERA: enthesitis related arthritis.
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a predictor of disability at 1 year in our multivariable
model. Although it was clear from looking at crude results
that certain subtypes had a more severe course over the
first year, there is likely to be much variability within each
subgroup. The common factor that linked all of these
subgroups to outcome was disease severity at first pre-
sentation. As many children may present with persistent
inflammatory arthritis and not fit into a specific ILAR
category, instead being classified as ‘Undifferentiated’,
we felt it important to include other easily measurable
factors, such as joint counts, pain score, disability and
ESR that are common to all children presenting with
inflammatory arthritis. With time, it may be more sensible
to include these subtypes into further predictive models.
In addition, there may be certain characteristics within
each subtype which may predict a worse disease
course, such as ANA or HLA-B27 status. For example,
33 of the 51 children with ERA had HLA-B27 test results,
of which 64% were positive.
Conclusions
This analysis has shown that even within a short 1-year
period following presentation with inflammatory arthritis,
the majority of children will have a significant improvement
in pain, joint inflammation and disability, with many
children having no active or limited joints. However, after
1 year, one-third of the children continued to have
moderate to severe levels of disability, despite treatment
with IA steroid injections or DMARDs. These higher levels
of disability were predicted by higher levels of CHAQ
at baseline, higher PGEs and female gender. Further
follow-up of this cohort will continue to explore the
longer term outcomes in these children and confirm
whether these same predictors (measured at first presen-
tation) or other factors, such as any delay to treatment, will
predict outcome of disability at later stages of the disease.
Rheumatology key messages
. Two-thirds of the children presenting with JIA will
have low levels of disability at the end of the first
year.
. Disability at first presentation is the strongest pre-
dictor of early persistent disability in children with
JIA.
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